

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-52. (Canceled)

Claim 53. (Currently amended) A method for inducing a cellular immune response in a human subject directed to a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, the subject having a cancer overexpressing the PSCA protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject dendritic cells pulsed with the PSCA protein of SEQ ID NO:2 or pulsed with an immunogenic fragment of the PSCA protein of SEQ ID NO:2, wherein the immunogenic fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2 ~~consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.~~

Claims 54 to 57. (Canceled)

Claim 58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claims 59 to 77. (canceled).

Claim 78. (Currently amended) A method for inducing an immune response in a mammalian subject directed to a PSCA protein of SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of SEQ ID NO:2 or an immunogenic fragment thereof wherein the fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2, wherein dendritic

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-52. (Canceled)

Claim 53. (Currently amended) A method for inducing a cellular immune response in a human subject directed to a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, the subject having a cancer overexpressing the PSCA protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject dendritic cells pulsed with the PSCA protein of SEQ ID NO:2 or pulsed with an immunogenic fragment of the PSCA protein of SEQ ID NO:2, wherein the immunogenic fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2 ~~consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.~~

Claims 54 to 57. (Canceled)

Claim 58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

Claims 59 to 77. (canceled).

Claim 78. (Currently amended) A method for inducing an immune response in a mammalian subject directed to a PSCA protein of SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO:2, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of SEQ ID NO:2 or an immunogenic fragment thereof wherein the fragment comprises amino acid residues 2 through 50 as described in SEQ ID NO:2, wherein dendritic